

ORIGINAL ARTICLE

Intravascular Complications of Central Venous Catheterization by Insertion Site

Jean-Jacques Parienti, M.D., Ph.D., Nicolas Mongardon, M.D.,
 Bruno Mégarbane, M.D., Ph.D., Jean-Paul Mira, M.D., Ph.D.,
 Pierre Kalfon, M.D., Ph.D., Antoine Gros, M.D., Sophie Marqué, M.D.,
 Marie Thuong, M.D., Véronique Pottier, M.D., Michel Ramakers, M.D.,
 Benoît Savary, M.D., Amélie Seguin, M.D., Xavier Valette, M.D.,
 Nicolas Terzi, M.D., Ph.D., Bertrand Sauneuf, M.D.,
 Vincent Cattoir, Pharm.D., Ph.D., Leonard A. Mermel, D.O.,
 and Damien du Cheyron, M.D., Ph.D., for the 3SITES Study Group*

ABSTRACT

BACKGROUND

The authors' affiliations are listed in the Appendix. Address reprint requests to Dr. Parienti at the Department of Biostatistics and Clinical Research, CHU de Caen, Ave. de la Côte de Nacre, Caen 14000, France, or at parienti-jj@chu-caen.fr.

Three anatomical sites are commonly used to insert central venous catheters, but insertion at each site has the potential for major complications.

METHODS

*A complete list of investigators in the 3SITES study is provided in the Supplementary Appendix, available at NEJM.org.

In this multicenter trial, we randomly assigned nontunneled central venous catheterization in patients in the adult intensive care unit (ICU) to the subclavian, jugular, or femoral vein (in a 1:1:1 ratio if all three insertion sites were suitable [three-choice scheme] and in a 1:1 ratio if two sites were suitable [two-choice scheme]). The primary outcome measure was a composite of catheter-related bloodstream infection and symptomatic deep-vein thrombosis.

Drs. Mermel and du Cheyron contributed equally to this article.

RESULTS

This article was updated on September 24, 2015, at NEJM.org.

A total of 3471 catheters were inserted in 3027 patients. In the three-choice comparison, there were 8, 20, and 22 primary outcome events in the subclavian, jugular, and femoral groups, respectively (1.5, 3.6, and 4.6 per 1000 catheter-days; $P=0.02$). In pairwise comparisons, the risk of the primary outcome was significantly higher in the femoral group than in the subclavian group (hazard ratio, 3.5; 95% confidence interval [CI], 1.5 to 7.8; $P=0.003$) and in the jugular group than in the subclavian group (hazard ratio, 2.1; 95% CI, 1.0 to 4.3; $P=0.04$), whereas the risk in the femoral group was similar to that in the jugular group (hazard ratio, 1.3; 95% CI, 0.8 to 2.1; $P=0.30$). In the three-choice comparison, pneumothorax requiring chest-tube insertion occurred in association with 13 (1.5%) of the subclavian-vein insertions and 4 (0.5%) of the jugular-vein insertions.

CONCLUSIONS

In this trial, subclavian-vein catheterization was associated with a lower risk of bloodstream infection and symptomatic thrombosis and a higher risk of pneumothorax than jugular-vein or femoral-vein catheterization. (Funded by the Hospital Program for Clinical Research, French Ministry of Health; ClinicalTrials.gov number, NCT01479153.)

N Engl J Med 2015;373:1220-9.
 DOI: 10.1056/NEJMoa1500964
 Copyright © 2015 Massachusetts Medical Society.

SUBCLAVIAN, JUGULAR, AND FEMORAL central venous catheterization are associated with infectious, thrombotic, and mechanical complications.¹ Catheter-related bloodstream infection has a significant effect on morbidity, mortality, and health care costs.²⁻⁴ The risk of short-term catheter-related bloodstream infection is influenced mainly by extraluminal microbial colonization of the insertion site,⁵ and such colonization is also associated with thrombosis.^{6,7} Although the importance of catheter-related deep-vein thrombosis has been debated,¹ all thromboses have the potential to embolize. In addition, catheter-related deep-vein thrombosis⁷⁻⁹ and pulmonary embolism¹⁰ may remain undiagnosed in critically ill patients undergoing mechanical ventilation.¹¹

We conducted the 3SITES multicenter study to evaluate the risk of catheter-related bloodstream infection or symptomatic catheter-related deep-vein thrombosis in adult patients who had been admitted to an intensive care unit (ICU). On the basis of our previous meta-analysis,¹² we hypothesized that the risk of these major complications would differ according to the site of catheter insertion.

METHODS

STUDY DESIGN AND OVERSIGHT

The 3SITES study was a multicenter randomized, controlled trial conducted in four university-affiliated hospitals and five general hospitals, representing 10 ICUs, in France from December 2011 through June 2014. The study was supported by funds from the French Ministry of Health Programme Hospitalier de Recherche Clinique National to the Délégation de la Recherche Clinique et de l'Innovation of the Caen University Hospital. The first author designed the study. CareFusion provided chlorhexidine products free of charge; no other commercial entity contributed to this trial. The research ethics committee at Caen University approved the study protocol (available with the full text of this article at NEJM.org) for all the participating centers. The first author analyzed the data and vouches for the accuracy and completeness of the reported data and for the fidelity of the study to the protocol.

PATIENTS AND RANDOMIZATION

Patients 18 years of age or older were eligible for the study if they were admitted to the ICU, re-

quired nontunneled central venous vascular access through a new venipuncture, and were considered by the physician inserting the catheter to be suitable candidates for venous catheterization in at least two of the following three sites: the subclavian veins, the jugular veins, or the femoral veins. The determination that a venous access site was suitable (or usable) for catheterization was based on clinician judgment. More than one catheter per patient could be included in the trial. Written informed consent was obtained from all participants or from their proxies in cases of impaired decision-making capacity at the time of enrollment.

If all three venous access sites (subclavian, jugular, and femoral) were considered suitable for catheter placement, the catheterization site was assigned in a 1:1:1 randomization scheme (three-choice scheme). If one of the three sites was not suitable on both the left and right sides of the body, the catheterization site was assigned in a 1:1 randomization scheme for the other two sites (two-choice scheme), an approach termed "selective exclusion."¹³ If only one site was suitable, that catheterization procedure was not included in the study. Randomization was stratified according to ICU and according to the use of antibiotic therapy versus no use of antibiotic therapy¹⁴; it was implemented by means of a centralized 24-hour, web-based or telephone interactive computerized response system (EOL, MedSharing), with the use of permuted-block randomization with varying block sizes.

TRIAL PROCEDURES

All participating ICUs followed the French Haute Autorité de Santé checklist¹⁵ and U.S. guidelines for preventing catheter-related infections.¹⁶ Residents or staff physicians who had performed at least 50 previous procedures inserted the catheters or supervised the catheterization in the ICU. Maximal sterile barrier precautions were used, including surgical hand antisepsis,¹⁷ sterile gloves, surgical long-sleeved gowns, caps, and masks. Patients were covered by sterile drapes. Antiseptics, dressing, and catheter products are listed according to participating ICU in Table S1 in the Supplementary Appendix, available at NEJM.org. None of the study catheters were antiseptic-impregnated, antibiotic-impregnated, or tunneled.

Catheterization was achieved by means of the Seldinger technique with the use of anatomical landmarks or ultrasonographic guidance. After

jugular and subclavian catheterizations, chest radiography was used to confirm the position of the catheter tip inside the superior vena cava and to assess for pneumothorax. Catheters were not used for routine blood sampling or renal replacement therapy.

Decisions to remove catheters were made independently by the physicians caring for each patient. After aseptic removal, the catheter tips were sent for quantitative culture.¹⁸ Peripheral blood for culture was systematically drawn at the time of catheter removal (details are provided in the Supplementary Appendix). Patients discharged from the ICU with the catheter in place had blood drawn for culture simultaneously from a peripheral vein and the central venous catheter to determine the differential time to positivity.

Within 2 days after removal of the catheter, compression ultrasonography was performed at the insertion site to confirm symptomatic catheter-related deep-vein thrombosis and to detect asymptomatic deep-vein thrombosis. Cases of symptomatic deep-vein thrombosis and cases of asymptomatic deep-vein thrombosis were combined for some analyses and referred to as total deep-vein thrombosis. Data on asymptomatic deep-vein thrombosis were missing for all patients who died or were discharged from the ICU with the catheter in place.

External, independent clinical monitors validated a randomly selected 12% of the data and all primary and secondary outcomes. Patients were followed until ICU discharge or death.

OUTCOMES

The primary outcome was the incidence of major catheter-related complications from the time of catheter insertion to 48 hours after catheter removal; major complications were defined as the composite of catheter-related bloodstream infection (*Medical Dictionary for Regulatory Activities* [MedDRA], version 17, code 10064687, grade 3 or higher) and symptomatic deep-vein thrombosis (MedDRA, version 17, code 10062169, grade 3 or higher), whichever occurred first (see the definitions in Table S2 in the Supplementary Appendix). Key secondary outcomes included the time to catheter-tip colonization and time to total deep-vein thrombosis after catheter removal.

A diagnosis of catheter-related bloodstream infection required catheter-tip colonization with the same phenotypic microorganism isolated from a peripheral blood culture.¹⁶ For a diagnosis

of catheter-related bloodstream infection with a potential skin contaminant, two separate peripheral-blood cultures had to grow the same microorganism that colonized the catheter tip. Colonization of the catheter tip was defined as 1000 or more colony-forming units per milliliter.¹⁸ An adjudication committee that was unaware of the study-group assignments reviewed all suspected cases of catheter-related bloodstream infection.

If a patient had signs or symptoms of catheter-related deep-vein thrombosis, compression ultrasonography was used to confirm the diagnosis. The ultrasonography-confirmed diagnosis served as the deep-vein thrombosis component of the primary outcome.

The secondary safety outcome was the rate of major mechanical complications (grade 3 or higher) during insertion of the central venous catheter and follow-up. Mechanical complications were defined in accordance with the modified National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (definitions are provided in Table S2 in the Supplementary Appendix), with the modification that pneumothorax requiring chest-tube insertion was classified as grade 3 instead of grade 2.

STATISTICAL ANALYSIS

Our sample-size estimation is described in the Supplementary Appendix. We estimated that a total sample of 3333 catheters was required, given our initial assumptions about the incidence of catheter-related complications.

The statistical unit of analysis was the catheter. Analyses followed the intention-to-treat principle. A per-protocol sensitivity analysis excluded catheters that were not inserted in the allocated site and side of the body because of failure to gain vascular access. For cases in which catheter-tip culture data and blood-culture data were missing, follow-up was censored at catheter removal or at ICU discharge with the catheter, whichever occurred first. Complete case and multiple-imputation sensitivity analyses were also performed (described in the Supplementary Appendix).

The incidence of the primary outcome was compared among the three insertion sites in the three-choice comparison with the use of the overall log-rank test. Pairwise comparisons were conducted (combining insertion-site groups from among the catheters that were randomized in the three-choice scheme with the relevant groups from




Figure 1. Screening and Randomization of Catheter Insertions.

Pairwise comparisons combine insertion-site groups from among the catheters that were randomized in the three-choice scheme with the relevant groups from the relevant two-choice scheme. For example, the subclavian insertion-site group that was included in the subclavian-versus-femoral pairwise comparison included 878 catheters: the 843 catheters assigned in the three-choice scheme (i.e., with all three sites available) plus the 35 catheters in patients for whom the jugular site was excluded.

the relevant two-choice scheme [Fig. 1]) with the use of a Cox model that included catheter site, stratification variables, and design variables (inclusion in the three-choice or the relevant two-choice scheme).¹³ A robust sandwich covariance estimate was used to account for a possible clustering effect of multiple catheters per patient. A subsample sensitivity analysis that included one randomly selected catheter per patient was performed. The proportionality assumption was confirmed visually and tested by including the site as a time-dependent covariate in the Cox model.

The intention-to-treat secondary safety outcome was analyzed by means of a random-intercept logistic regression. Planned subgroup analyses of the primary outcome were conducted by testing the

interaction term between each pairwise comparison and the use of alcoholic chlorhexidine for cutaneous antisepsis,¹⁹⁻²¹ antibiotic treatment,¹⁴ anticoagulation, body-mass index (the weight in kilograms divided by the square of the height in meters) greater than 28,⁹ and selective site exclusion.¹³ Similarly, subgroup analyses for the secondary safety outcome were conducted according to whether ultrasonography was used to guide insertion.²²

We used SAS software, version 9.4 (SAS institute), for the statistical analyses. The Holm-Bonferroni method²³ was used to account for multiple testing of the primary outcome in the two superiority pairwise comparisons. Therefore, a P value of less than 0.025 was considered to indicate statistical significance for the lower P value,

Table 1. Characteristics of the Patients at Baseline.*

Characteristic	Three-Choice Comparison			Pairwise Comparison†			Pairwise Comparison‡		
	Jugular (N=845)	Femoral (N=844)	Subclavian (N=843)	Femoral (N=875)	Subclavian (N=878)	Jugular (N=984)	Subclavian (N=981)	Femoral (N=1140)	Jugular (N=1145)
Age	63.0±16.3	63.5±15.3	62.9±15.9	63.3±15.5	62.8±15.8	63.0±16.1	62.5±15.8	63.0±15.1	63.1±16.1
Male — no. (%)	531 (62.8)	545 (64.6)	543 (64.4)	572 (65.4)	570 (64.9)	621 (63.1)	635 (64.7)	748 (65.6)	721 (63.0)
SAPS II‡	57.1±19.4	56.1±18.9	55.1±20.2	56.1±18.9	55.2±20.1	56.9±19.6	54.8±20.2	57.3±19.7	57.7±20.3
Body-mass index	26.1±5.7	25.8±5.5	25.9±5.3	25.9±5.5	25.9±5.3	26.2±5.8	26.4±5.8	25.9±5.5	26.1±5.7
Diabetes mellitus — no. (%)	173 (20.5)	175 (20.7)	151 (17.9)	182 (20.8)	161 (18.3)	214 (21.7)	188 (19.2)	238 (20.9)	236 (20.6)
Cancer — no. (%)	76 (9.0)	96 (11.4)	74 (8.8)	97 (11.1)	77 (8.8)	82 (8.3)	83 (8.5)	140 (12.3)	120 (10.5)
AIDS — no. (%)	12 (1.4)	8 (0.9)	13 (1.5)	8 (0.9)	15 (1.7)	12 (1.2)	13 (1.3)	12 (1.1)	15 (1.3)
Neutrophil count <500/mm ³ — no. (%)	15 (1.8)	11 (1.3)	6 (0.7)	11 (1.3)	6 (0.7)	16 (1.6)	6 (0.6)	26 (2.3)	36 (3.1)
Tracheotomy — no. (%)	14 (1.7)	17 (2.0)	19 (2.3)	23 (2.6)	25 (2.8)	18 (1.8)	23 (2.3)	22 (1.9)	22 (1.9)
Antibiotic therapy — no. (%)	457 (54.1)	472 (55.9)	466 (55.3)	489 (55.9)	487 (55.5)	545 (55.4)	555 (56.6)	656 (57.5)	647 (56.5)
Anticoagulation therapy — no. (%)	257 (30.4)	259 (30.7)	249 (29.5)	272 (31.1)	259 (29.5)	308 (31.3)	311 (31.7)	368 (32.3)	365 (31.9)
Parenteral nutrition — no. (%)	49 (5.8)	61 (7.2)	47 (5.6)	68 (7.8)	56 (6.4)	67 (6.8)	72 (7.3)	70 (6.1)	62 (5.4)

* Plus-minus values are means ±SD. Numbers in the table are numbers of catheters; therefore, some patients are included more than once. The lack of independence between observations was taken into account in the generalized-estimating-equation models for the comparisons between groups, and none of the variables differed significantly between groups in these models. † These comparisons combine insertion-site groups from among the catheters that were randomized in the three-choice scheme with the relevant groups from the relevant two-choice scheme. ‡ SAPS II denotes Simplified Acute Physiology Score II (values range from 0 to 163 points, with higher scores indicating a higher risk of death).

and a P value of less than 0.05 was considered to indicate significance for the higher P value.

RESULTS

BASELINE AND PROCEDURAL CHARACTERISTICS AND FOLLOW-UP

A total of 3027 patients were included in the study. A total of 3471 catheters (1284 jugular, 1171 femoral, and 1016 subclavian) were included, of which 2532 (72.9%) were randomly assigned in the three-choice scheme (845 jugular, 844 femoral, and 843 subclavian) (Fig. 1). The reasons for excluding one of the three sites are provided in the Table S3 in the Supplementary Appendix. Catheters were inserted in the randomly assigned site and side in 3154 cases (90.9%) overall, including 866 cases (85.2%) assigned to the subclavian site, 1174 cases (91.4%) assigned to the jugular site, and 1114 cases (95.1%) assigned to the femoral site (Fig. 1).

The characteristics of the patients at baseline according to the site of catheter insertion were well balanced between the groups within the three-choice comparison and the three pairwise comparisons (Table 1). Catheter-related and procedural characteristics are shown in Table 2. The use of anatomical landmarks was more frequent in the subclavian and femoral groups than in the jugular group. Catheterization was performed more quickly in the femoral group than in either of the other two groups. Alcohol-based products were the predominant cutaneous antiseptics used for cleaning the catheter insertion site; the frequency of the use of chlorhexidine-containing products was similar among the different insertion sites.

The median duration of catheter use was 5 days for each of the three insertion sites (Table 2). No patients were lost to follow-up. Catheter-tip cultures and peripheral-blood cultures were missing in 101 cases (2.9%). Data on asymptomatic deep-vein thrombosis were missing in 2049 cases (59.0%).

CATHETER-RELATED INFECTION AND SYMPTOMATIC DEEP-VEIN THROMBOSIS

In the three-choice comparison, there were 50 nonduplicate primary outcome events (i.e., events that did not occur in the same catheter), and their incidence differed according to the randomly assigned site of catheter insertion, with 8 events in the subclavian group, 20 events in the jugular group, and 22 events in the femoral group (1.5, 3.6, and 4.6 per 1000 catheter-days, respectively;

Table 2. Catheter-Related and Procedural Characteristics.*

Characteristic	Three-Choice Comparison			Pairwise Comparison†			Pairwise Comparison‡		
	Jugular (N = 845)	Femoral (N = 844)	Subclavian (N = 843)	Femoral (N = 875)	Subclavian (N = 878)	Jugular (N = 984)	Subclavian (N = 981)	Femoral (N = 1140)	Jugular (N = 1145)
Skin antiseptics and catheter care — no. (%)‡									
Alcoholic chlorhexidine	366 (43.3)	363 (43.0)	380 (45.1)	372 (42.5)	391 (44.5)	439 (44.6)	435 (44.3)	468 (41.1)	477 (41.7)
Alcoholic povidone-iodine	364 (43.1)	361 (42.8)	355 (42.1)	383 (43.8)	374 (42.6)	426 (43.3)	421 (42.9)	500 (43.9)	498 (43.5)
Aqueous povidone-iodine	83 (9.8)	86 (10.2)	82 (9.7)	86 (9.8)	87 (9.9)	86 (8.7)	95 (9.7)	134 (11.8)	131 (11.4)
Other or unknown	32 (3.8)	34 (4.0)	26 (3.1)	34 (3.9)	26 (3.0)	33 (3.4)	30 (3.1)	38 (3.3)	39 (3.4)
Use of anatomical landmarks to guide insertion — no. (%)§	276 (32.7)¶	623 (73.8)¶	723 (85.8)¶	648 (74.1)¶	758 (86.3)¶	314 (31.9)¶	847 (86.3)¶	825 (72.4)¶	360 (31.4)¶
Time for insertion — min	12.6±9.1¶	11.6±9.0¶	12.8±9.2¶	11.6±9.0¶	12.8±9.3¶	12.8±9.5	12.8±9.2	11.7±9.0¶	12.7±9.5¶
Insertion failure — no. (%)	65 (7.7)¶	45 (5.3)¶	124 (14.7)¶	45 (5.1)¶	126 (14.3)¶	75 (7.6)¶	148 (15.1)¶	57 (5.0)¶	100 (8.7)¶
Duration of catheterization — days									
Mean	6.5±5.6	5.9±4.8	6.4±5.3	5.9±4.8¶	6.5±5.4¶	6.7±5.8	6.8±5.7	5.8±4.8¶	6.5±5.4¶
Median (range)	5 (3–9)	5 (2–8)	5 (3–9)	5 (3–9)	5 (2–8)	5 (3–9)	5 (3–9)	5 (2–8)	5 (3–9)
Reason for catheter removal — no. (%)									
No longer required	497 (58.8)	492 (58.3)	485 (57.5)	505 (57.7)	500 (56.9)	570 (57.9)	547 (55.8)	624 (54.7)	641 (56.0)
Death	181 (21.4)	137 (16.2)	151 (17.9)	142 (16.2)	159 (18.1)	211 (21.4)	175 (17.8)	223 (19.6)	259 (22.6)
Suspected catheter infection	89 (10.5)	112 (13.2)	109 (12.9)	119 (13.6)	118 (13.4)	111 (11.3)	143 (14.6)	157 (13.8)	135 (11.8)
Systematic	18 (2.1)	22 (2.6)	20 (2.4)	22 (2.5)	21 (2.4)	19 (1.9)	25 (2.5)	27 (2.4)	26 (2.3)
Other or unknown	60 (7.1)	81 (9.6)	78 (9.3)	87 (9.9)	80 (9.1)	73 (7.4)	91 (9.3)	109 (9.6)	84 (7.3)

* Plus-minus values are means ±SD.


† These comparisons combine insertion-site groups from among the catheters that were randomized in the three-choice scheme with the relevant groups from the relevant two-choice scheme.

‡ Alcoholic chlorhexidine included 2% chlorhexidine with 70% isopropyl alcohol used in a one-step procedure, 0.5% chlorhexidine with 70% ethanol and 0.25% chlorhexidine, 0.025% benzalkonium chloride with 4% benzyl alcohol, both used in a four-step procedure. Alcoholic povidone-iodine included 5% povidone-iodine with 70% ethanol used in a four-step procedure. Aqueous povidone-iodine included 10% povidone-iodine used in a four-step procedure.

§ Other catheters were inserted with the use of ultrasonography.

¶ Results between groups were significant at P<0.05, as assessed with the use of generalized-estimating-equation models for each group comparison.

|| Systematic refers to catheter removal after a certain period to prevent catheter complications.



$P=0.02$) (Fig. 2). Corresponding Kaplan–Meier curves showed a constant increase in risk for each insertion-site group (Fig. S1 and S2 in the Supplementary Appendix). In pairwise comparisons for the primary outcome in groups from the three-choice and two-choice schemes combined (Table 3), the risk of the primary outcome was significantly higher in the femoral group than in the subclavian group (hazard ratio, 3.5; 95% confidence interval [CI], 1.5 to 7.8; $P=0.003$) and in the jugular group than in the subclavian group (hazard ratio, 2.1; 95% CI, 1.0 to 4.3; $P=0.04$), whereas the risk in the femoral group was similar to that in the jugular group (hazard ratio, 1.3; 95% CI, 0.8 to 2.1; $P=0.30$).

In a sensitivity analysis that included one randomly selected catheter per patient, the results were consistent with those in the primary analysis (Table S4 in the Supplementary Appendix). Differences between the subclavian group and the other two groups were larger in the per-protocol sensitivity analysis (Table S5 in the Supplementary Appendix), because half of the catheter-related bloodstream infections in the subclavian group occurred in catheters that were, in fact, inserted elsewhere. The results of complete-case and multiple-imputation sensitivity analyses were consistent with those in the primary analysis (Table S6 in the Supplementary Appendix).

The results for the secondary outcomes of catheter-tip colonization and total deep-vein thrombosis also favored the subclavian group (Table 3). Kaplan–Meier curves of these data are shown in Figures S3 and S4 in the Supplementary Appendix, respectively. The causative pathogens identified in each case of catheter-related bloodstream infection and catheter-tip colonization are shown in Table S7 in the Supplementary Appendix. Among the 171 blood samples drawn for culture to determine the differential time to positivity in patients discharged from the ICU with their central venous catheter in place, the one catheter-related bloodstream infection identified with the use of this method was subsequently confirmed in a catheter-tip culture.

MECHANICAL COMPLICATIONS

The frequency of major mechanical complications in the three-choice comparison (Fig. 2) differed according to insertion-site group ($P=0.047$), with 18 events in the subclavian group, 12 events in the jugular group, and 6 events in the femoral group. Pneumothorax accounted for 13 events in the subclavian group and 4 events in the jugular group. In the pairwise comparisons (Table 3), there were significantly fewer mechanical complications in the femoral group than in the subclavian group (odds ratio, 0.3; 95% CI, 0.1 to 0.8; $P=0.03$), but there were no significant differences in the other pairwise comparisons.

SUBGROUP ANALYSES

None of the preplanned subgroup analyses showed a significant interaction for the primary outcome (Table S9 in the Supplementary Appendix). With regard to major mechanical complications, there was a significant interaction between the use of ultrasonography and the comparison between the femoral group and the jugular group ($P=0.007$), as well as a nonsignificant trend for an interaction between the use of ultrasonography and the comparison between the femoral group and the subclavian group ($P=0.07$); the differences between the groups in these two comparisons were larger when ultrasonography was not used to guide catheter insertion (Table S9 in the Supplementary Appendix).

DISCUSSION

In this randomized, controlled trial, catheterization of the subclavian vein was associated

Table 3. Intention-to-Treat Pairwise Comparisons for the Trial Outcomes.

Outcome	Femoral versus Subclavian			Jugular versus Subclavian			Femoral versus Jugular					
	Femoral number	Subclavian number	Hazard Ratio (95% CI)*	P Value	Jugular number	Subclavian number	Hazard Ratio (95% CI)*	P Value	Femoral number	Jugular number	Hazard Ratio (95% CI)*	P Value
Catheters	875	878	—	—	984	981	—	—	1140	1145	—	—
Catheter-days	5198	5739	—	—	6573	6651	—	—	6658	7427	—	—
Primary composite outcome†	25	8	3.5 (1.5–7.8)	0.003	23	11	2.1 (1.0–4.3)	0.04	33	30	1.3 (0.8–2.1)	0.30
Bloodstream infection	11	4	3.4 (1.0–11.1)	0.048	13	6	2.3 (0.8–6.2)	0.11	15	21	0.9 (0.5–1.8)	0.81
Symptomatic deep-vein thrombosis	15	5	3.4 (1.2–9.3)	0.02	10	6	1.8 (0.6–4.9)	0.29	20	9	2.4 (1.1–5.4)	0.04
Secondary outcome												
Catheter-tip colonization	107	39	3.4 (2.4–5.0)	<0.001	104	42	2.5 (1.7–3.5)	<0.001	145	121	1.6 (1.2–2.0)	0.003
Deep-vein thrombosis‡	46	19	3.0 (1.7–5.3)	<0.001	69	20	3.1 (1.9–5.0)	<0.001	62	78	0.9 (0.7–1.3)	0.68
Major mechanical complications	6	18	0.3 (0.1–0.8)§	0.03	12	22	0.5 (0.3–1.1)§	0.09	7	13	0.5 (0.2–1.4)§	0.19
Arterial injury	4	1	—	—	2	2	—	—	4	2	—	—
Hematoma	0	1	—	—	4	1	—	—	0	4	—	—
Pneumothorax	NA	13	—	—	4	14	—	—	NA	4	—	—
Miscellaneous¶	2	3	—	—	2	5	—	—	3	3	—	—

* Values in this column are hazard ratios unless otherwise indicated. All hazard ratios were adjusted for stratification variables (intensive care unit and antibiotic use) and design variables (three-choice vs. two-choice scheme). The confidence intervals for hazard ratios are robust confidence intervals taking into account multiple catheters per patient. NA denotes not applicable.

† Some catheters had two events.
‡ The numbers of ultrasonographic evaluations in the three pairwise comparisons were 744 (398 in the femoral group and 346 in the subclavian group), 786 (399 in the jugular group and 387 in the subclavian group), and 955 (497 in the femoral group and 458 in the jugular group).

§ The value for major mechanical complications is an odds ratio computed by random-intercept logistic regression, rather than a hazard ratio.

¶ The specific miscellaneous mechanical complications for each pairwise comparison are listed in Table S8 in the Supplementary Appendix.

with a reduced risk of the combined outcome of catheter-related bloodstream infection and symptomatic deep-vein thrombosis. This was true in a comparison with femoral-vein catheterization, as others have suggested,⁸ but also in a comparison with jugular-vein catheterization. These findings are consistent with the Centers for Disease Control and Prevention guideline for preventing intravascular catheter-related infections, in which the recommendation is to “use a subclavian site, rather than a jugular or a femoral site, in adult patients.”¹⁶ However, subclavian-vein catheterization was associated with an increased risk of mechanical complications.

The low incidence of catheter-related bloodstream infection in the ICUs in our study is consistent with data from other ICUs.²⁴ Moreover, the differences in the incidences of catheter-related bloodstream infection and symptomatic deep-vein thrombosis according to insertion site are consistent with the differences found in catheter-tip colonization and total deep-vein thrombosis. Of note, the incidence of total deep-vein thrombosis should be interpreted with caution, because more than half of the inserted catheters had missing data for this secondary outcome, entirely because of missing data for asymptomatic patients.

There are probably several factors contributing to our findings. The subcutaneous course of the subclavian catheter before entry into the vein is generally longer than for the other two types. The subclavian insertion site has the lowest bacterial bioburden^{25,26} and is relatively protected against dressing disruption.²⁷ Finally, subclavian catheters are associated with less thrombosis.^{7,8}

The overall risk of mechanical, infectious, and thrombotic complications of grade 3 or higher was similar among the three insertion sites (Fig. 2), which suggests that an ideal site for central venous catheter insertion does not exist when all types of complications are considered to be of equal concern. However, the expected duration of catheterization is important, because the cumulative risk of infectious and thrombotic complications increases with increasing catheter exposure, whereas the risk of mechanical complications does not. Furthermore, the mechanical complications associated with subclavian catheter insertion can be limited by ultrasono-

graphic guidance^{28,29} and physician experience with the procedure.³⁰ Pneumothorax, which accounted for most of the difference in mechanical complications among insertion sites in our study, can be diagnosed promptly and treated immediately. This may not be the case for catheter-related bloodstream infection or deep-vein thrombosis. Decisions regarding the choice of insertion site should therefore be considered on a case-by-case basis.

A number of limitations of this trial should be considered. The use of ultrasonographic guidance during catheter insertion was not randomized. This may have influenced the risk of mechanical and infectious complications found in this study, although the reduction in catheter infection risk associated with the use of ultrasonography that was found in one randomized study²² was not confirmed in a subsequent large observational study.³¹ Daily chlorhexidine bathing^{32,33} and chlorhexidine-impregnated dressings³⁴ were not used. Whether these measures influence the difference in infectious risk between insertion sites is unknown. Last, we did not study the use of peripherally inserted central venous catheters. Peripherally inserted central venous catheters have been associated with a risk of infection similar to that associated with central venous catheters among patients in the ICU and with a higher risk of thrombosis.^{35,36}

In conclusion, in the 3SITES study, we found that catheterization of the subclavian vein was associated with a lower risk of the composite outcome of catheter-related bloodstream infection and symptomatic deep-vein thrombosis than that associated with catheterization of either the jugular vein or femoral vein. However, subclavian-vein catheterization was associated with a higher risk of mechanical complications, primarily pneumothorax.

Supported by a grant (PHRC-N 2010, 06-03) from the Hospital Program for Clinical Research, French Ministry of Health.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank Cynthia T. Crosby, Ph.D. (Department of Clinical Research, CareFusion, San Diego, CA), for providing alcoholic chlorhexidine (ChloroPrep, CareFusion) at no cost; Caroline Sabin, Ph.D. (Royal Free Campus, London), who reviewed an earlier version of the manuscript; Christian Brun-Buisson, M.D., Ph.D. (Hôpital Henri Mondor, Créteil), and Jean-François Timsit, M.D., Ph.D. (Hôpital Bichat, Paris), for reviewing the initial protocol and providing supporting comments; and the nursing and medical staff members of all the participating centers for their dedication and the study participants and their family members, without whom this study could not have been completed.

APPENDIX

The authors' affiliations are as follows: the Departments of Biostatistics and Clinical Research (J.-J.P.), Infectious Diseases (J.-J.P.), Surgical Intensive Care (V.P.), Medical Intensive Care (A.S., X.V., N.T., B. Sauneuf, D.C.), and Microbiology (V.C.), Centre Hospitalier

Universitaire (CHU) Caen, INSERM Unité Mixte de Recherche Scientifique 1075 COMETE (N.T.) and EA4655 Risques Microbiens (J.-J.P., V.C., D.C.), Université de Caen Normandie, Caen, Department of Medical Intensive Care, CHU Cochin (N.M., J.-P.M.), and Department of Medical and Toxicologic Intensive Care, CHU Lariboisière (B.M.), Paris, Department of Anesthesiology and Surgical Intensive Care, CHU Mondor, Créteil (N.M.), Department of Intensive Care Medicine, Centre Hospitalier Général, Chartres (P.K.), Department of Intensive Care Medicine, Centre Hospitalier Général, Versailles (A.G.), Department of Intensive Care Medicine, Centre Hospitalier Général, Corbeil-Essonnes (S.M.), Department of Intensive Care Medicine, Centre Hospitalier Général, Pontoise (S.M.), and Department of Intensive Care Medicine, Centre Hospitalier Général, Saint-Lô (M.R., B. Savary) — all in France; and the Rhode Island Hospital Department of Medicine, Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence (L.A.M.).

REFERENCES

- McGee DC, Gould MK. Preventing complications of central venous catheterization. *N Engl J Med* 2003;348:1123-33.
- Mermel LA. Prevention of intravascular catheter-related infections. *Ann Intern Med* 2000;132:391-402. [Erratum, *Ann Intern Med* 2000;133:395.]
- Siempos II, Kopterides P, Tsangaris I, Dimopoulou I, Armaganidis AE. Impact of catheter-related bloodstream infections on the mortality of critically ill patients: a meta-analysis. *Crit Care Med* 2009;37:2283-9.
- Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. *JAMA Intern Med* 2013;173:2039-46.
- Mermel LA. What is the predominant source of intravascular catheter infections? *Clin Infect Dis* 2011;52:211-2.
- Raad II, Luna M, Khalil SA, Costerton JW, Lam C, Bodey GP. The relationship between the thrombotic and infectious complications of central venous catheters. *JAMA* 1994;271:1014-6.
- Timsit JF, Farkas JC, Boyer JM, et al. Central vein catheter-related thrombosis in intensive care patients: incidence, risk factors, and relationship with catheter-related sepsis. *Chest* 1998;114:207-13.
- Merrer J, De Jonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. *JAMA* 2001;286:700-7.
- Parietti J-J, Thirion M, Mégarbane B, et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. *JAMA* 2008;299:2413-22.
- Minet C, Lugosi M, Savoye PY, et al. Pulmonary embolism in mechanically ventilated patients requiring computed tomography: prevalence, risk factors, and outcome. *Crit Care Med* 2012;40:3202-8.
- Cook DJ, Crowther MA. Thromboprophylaxis in the intensive care unit: focus on medical-surgical patients. *Crit Care Med* 2010;38:Suppl:S76-S82.
- Parietti J-J, du Cheyron D, Timsit J-F, et al. Meta-analysis of subclavian insertion and nontunneled central venous catheter-associated infection risk reduction in critically ill adults. *Crit Care Med* 2012;40:1627-34.
- Law MG, Emery S. Selective exclusion of treatment arms in multi-arm randomized clinical trials. *Stat Med* 2003;22:19-30.
- Souweine B, Heng AE, Aumeran C, et al. Do antibiotics administered at the time of central venous catheter removal interfere with the evaluation of colonization? *Intensive Care Med* 2008;34:286-91.
- French Haute Autorité de Santé. Checklist: pose d'un catheter veineux central (CVC) ou autre dispositif vasculaire (DV) (http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-01/11_01_check-list-cvc-dv.pdf).
- O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. *Am J Infect Control* 2011;39:Suppl 1:S1-S34.
- Parietti JJ, Thibon P, Heller R, et al. Hand-rubbing with an aqueous alcoholic solution vs traditional surgical hand-scrubbing and 30-day surgical site infection rates: a randomized equivalence study. *JAMA* 2002;288:722-7.
- Brun-Buisson C, Abrouk F, Legrand P, Huet Y, Larabi S, Rapin M. Diagnosis of central venous catheter-related sepsis: critical level of quantitative tip cultures. *Arch Intern Med* 1987;147:873-7.
- Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. *Ann Intern Med* 2002;136:792-801.
- Parietti J-J, du Cheyron D, Ramakers M, et al. Alcoholic povidone-iodine to prevent central venous catheter colonization: a randomized unit-crossover study. *Crit Care Med* 2004;32:708-13.
- Maiwald M, Chan ESY. The forgotten role of alcohol: a systematic review and meta-analysis of the clinical efficacy and perceived role of chlorhexidine in skin antisepsis. *PLoS One* 2012;7(9):e44277.
- Karakitsos D, Labropoulos N, De Groot E, et al. Real-time ultrasound-guided catheterisation of the internal jugular vein: a prospective comparison with the landmark technique in critical care patients. *Crit Care* 2006;10:R162.
- Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. *Am J Public Health* 1996;86:726-8.
- Vital signs: central line-associated blood stream infections — United States, 2001, 2008, and 2009. *MMWR Morb Mortal Wkly Rep* 2011;60:243-8.
- Moro ML, Viganò EF, Cozzi Lepri A. Risk factors for central venous catheter-related infections in surgical and intensive care units. *Infect Control Hosp Epidemiol* 1994;15:253-64.
- Kwakman PH, Müller MC, Binnekade JM, et al. Medical-grade honey does not reduce skin colonization at central venous catheter-insertion sites of critically ill patients: a randomized controlled trial. *Crit Care* 2012;16:R214.
- Timsit J-F, Bouadma L, Ruckly S, et al. Dressing disruption is a major risk factor for catheter-related infections. *Crit Care Med* 2012;40:1707-14.
- Fragou M, Gravvanis A, Dimitriou V, et al. Real-time ultrasound-guided subclavian vein cannulation versus the landmark method in critical care patients: a prospective randomized study. *Crit Care Med* 2011;39:1607-12.
- O'Leary R, Ahmed SM, McLure H, et al. Ultrasound-guided infraclavicular axillary vein cannulation: a useful alternative to the internal jugular vein. *Br J Anaesth* 2012;109:762-8.
- Eisen LA, Narasimhan M, Berger JS, Mayo PH, Rosen MJ, Schneider RF. Mechanical complications of central venous catheters. *J Intensive Care Med* 2006;21:40-6.
- Cartier V, Haenny A, Inan C, Walder B, Zingg W. No association between ultrasound-guided insertion of central venous catheters and bloodstream infection: a prospective observational study. *J Hosp Infect* 2014;87:103-8.
- Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. *N Engl J Med* 2013;368:533-42.
- Noto MJ, Domenico HJ, Byrne DW, et al. Chlorhexidine bathing and health care-associated infections: a randomized clinical trial. *JAMA* 2015;313:369-78.
- Timsit J-F, Schwebel C, Bouadma L, et al. Chlorhexidine-impregnated sponges and less frequent dressing changes for prevention of catheter-related infections in critically ill adults: a randomized controlled trial. *JAMA* 2009;301:1231-41.
- Chopra V, O'Horo JC, Rogers MAM, Maki DG, Safdar N. The risk of bloodstream infection associated with peripherally inserted central catheters compared with central venous catheters in adults: a systematic review and meta-analysis. *Infect Control Hosp Epidemiol* 2013;34:908-18.
- Chopra V, Anand S, Hickner A, et al. Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. *Lancet* 2013;382:311-25.

Copyright © 2015 Massachusetts Medical Society.

CORRESPONDENCE



Complications of Central Venous Catheterization

TO THE EDITOR: The results of the randomized trial by Parienti et al. (Sept. 24 issue)¹ comparing insertion sites for central venous catheterization will help guide clinicians in their choice of sites. We were surprised, however, that the authors did not report the number of patients in each insertion-site group who were receiving positive-pressure ventilation. The increased positive end-expiratory pressure and large tidal volumes associated with mechanical ventilation can predispose a patient to the development of pneumothorax. Some evidence suggests that the risk of pneumothorax from subclavian-vein catheterization may be higher among patients receiving positive-pressure ventilation than among those not receiving it.² Without knowing how the outcomes are stratified according to ventilation status, it is hard to fairly assess the true risk profile of subclavian-vein access.

The authors correctly observe that “the cumulative risk of infectious and thrombotic complications increases with increasing catheter exposure.” We think the inference is worth stating more plainly: one means of preventing infectious complications from central venous catheterization is prompt removal of the catheter when it is no longer needed.³

David R. Vinson, M.D.

Dustin W. Ballard, M.D., M.B.E.

Permanente Medical Group
Oakland, CA
drvinson@ucdavis.edu

Michael K. Gould, M.D.

Kaiser Permanente Southern California
Pasadena, CA

No potential conflict of interest relevant to this letter was reported.

1. Parienti JJ, Mongardon N, Mégarbane B, et al. Intravascular complications of central venous catheterization by insertion site. *N Engl J Med* 2015;373:1220-9.

2. Vinson DR, Ballard DW, Hance LG, et al. Pneumothorax is a rare complication of thoracic central venous catheterization in community EDs. *Am J Emerg Med* 2015;33:60-6.

3. McGee DC, Gould MK. Preventing complications of central venous catheterization. *N Engl J Med* 2003;348:1123-33.

DOI: 10.1056/NEJMc1600131

TO THE EDITOR: We are concerned with the reporting by Parienti and colleagues of central-catheter-associated bloodstream infections with the use of *Medical Dictionary for Regulatory Activities* definitions. These rates are inconsistent with contemporaneous American and Australian data on central-catheter-associated bloodstream infections defined according to the Centers for Disease Control and Prevention (CDC).^{1,2}

Data from the Victorian Healthcare Associated Infection Surveillance System, based on 303,968 days of central venous catheter use at 29 intensive care units (ICUs) from 2009 through 2013, showed the statewide rate of catheter-associated bloodstream infections to be 1.26 per 1000 catheter-days.² This is approximately 60% of the aggregate 2.0 bloodstream infections per 1000 catheter-days reported in the 3SITES trial by Parienti et al.

Our institution is a typical Australian tertiary referral center. Local protocols for the insertion of central venous catheters mandate the following: skin preparation with topical chlorhexidine, chlorhexidine-impregnated catheters, and ultrasonographic guidance.³ The rate of central-catheter-associated bloodstream infections in local ICUs is 1.1 per 1000 catheter-days overall. Moreover, the rate of attributable iatrogenic pneumothorax in our ICU was 0 per 2221 insertions of central venous catheters from 2013 through 2015. We suggest that the findings of

THIS WEEK'S LETTERS

- 1489 **Complications of Central Venous Catheterization**
- 1492 **Pregnancy, Primary Aldosteronism, and Somatic CTNFB1 Mutations**
- 1495 **Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis**
- 1496 **Multiple Sclerosis and Antibodies against KIR4.1**

the 3SITES trial are of limited external validity to jurisdictions and sites that apply the above catheter-insertion principles and different definitions of central-catheter-associated bloodstream infections.

Karen F. Urbancic, M.Clin.Pharm.

Ray Robbins, Ph.D.

Austin Health
Melbourne, VIC, Australia

Neil J. Glassford, M.B., Ch.B.

Monash University
Melbourne, VIC, Australia
drneilglassford@gmail.com

No potential conflict of interest relevant to this letter was reported.

1. Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. *N Engl J Med* 2013;368:533-42.
2. Worth LJ, Spelman T, Bull AL, Brett JA, Richards MJ. Central line-associated bloodstream infections in Australian intensive care units: time-trends in infection rates, etiology, and antimicrobial resistance using a comprehensive Victorian surveillance program, 2009–2013. *Am J Infect Control* 2015;43:848-52.
3. Australian and New Zealand Intensive Care Society Safety and Quality Committee. Central line insertion and maintenance guideline. Melbourne, VIC, Australia: ANZICS, 2012 (http://www.anzics.com.au/Downloads/ANZICS_Insertion&maintenance_guideline2012_04.pdf).

DOI: 10.1056/NEJMc1600131

TO THE EDITOR: The 3SITES trial provides site-specific complication rates after central venous catheterization and suggests the preferential use of the subclavian vein in critical illness. Not considered, however, are long-term complications, which might influence the choice of site, particularly in the subgroup of patients who are likely to require long-term dialysis.

Chronic central-vein stenosis is asymptomatic in many persons but leads to malfunction of surgically created arteriovenous fistulae in patients receiving dialysis, in whom it often recurs after venoplasty. Central-vein stenosis is particularly associated with catheters in the subclavian vein (as opposed to the internal jugular or femoral vein),^{1,2} regardless of catheter size, even after short-term use.³

This is of relevance to a growing proportion of patients: between 1996 and 2010, the percentage of critically ill patients who initiated dialysis during intensive care increased by a factor of almost 4, with up to a quarter of surviving patients remaining permanently dependent on dialysis.⁴ The subclavian venous site may provide short-term benefits, but in those who may face permanent renal failure, this site has longer-term disadvantages that need consideration.

Richard W. Corbett, M.R.C.P.

Damien R. Ashby, M.R.C.P., Ph.D.

Hammersmith Hospital
London, United Kingdom
rcorbett@imperial.ac.uk

No potential conflict of interest relevant to this letter was reported.

1. Hernández D, Díaz F, Rufino M, et al. Subclavian vascular access stenosis in dialysis patients: natural history and risk factors. *J Am Soc Nephrol* 1998;9:1507-10.
2. Schillinger F, Schillinger D, Montagnac R, Milcent T. Post catheterisation vein stenosis in haemodialysis: comparative angiographic study of 50 subclavian and 50 internal jugular accesses. *Nephrol Dial Transplant* 1991;6:722-4.
3. Cimochoowski GE, Worley E, Rutherford WE, Sartain J, Blondin J, Harter H. Superiority of the internal jugular over the subclavian access for temporary dialysis. *Nephron* 1990;54:154-61.
4. Wald R, McArthur E, Adhikari NKJ, et al. Changing incidence and outcomes following dialysis-requiring acute kidney injury among critically ill adults: a population-based cohort study. *Am J Kidney Dis* 2015;65:870-7.

DOI: 10.1056/NEJMc1600131

TO THE EDITOR: In the trial reported by Parienti and colleagues, the authors conclude that subclavian catheterization was associated with a higher risk of pneumothorax than was jugular or femoral catheterization. We believe that this conclusion concerning the pneumothorax rate cannot be generalized to other ICUs for a number of reasons: both French and U.S. guidelines recommend the use of the ultrasonography-guided technique for all sites, but only 15% of the subclavian procedures in the present trial were performed with ultrasonographic guidance^{1,2}; it cannot be ruled out that the ultrasonography-guided technique was preferentially chosen by operators in patients who presented with risk factors for pneumothorax (e.g., obesity or emphysema); and the incidence of pneumothorax in subclavian procedures reported here was 1.5%, whereas in studies using ultrasonography-guided subclavian procedures, the rate was between 0 and 0.2%, similar to the pneumothorax rate reported in the jugular site in the present trial.^{3,4} For all these reasons, the authors' conclusion that subclavian procedures are associated with an increased risk of pneumothorax pertains only to physicians using the nonrecommended landmark technique.

Julien Maizel, M.D., Ph.D.

Michel Slama, M.D., Ph.D.

Centre Hospitalier Universitaire d'Amiens
Amiens, France
maizel.julien@chu-amiens.fr

No potential conflict of interest relevant to this letter was reported.

1. Haute Autorité de Santé. Check-list: pose d'un catheter

veineux central (CVC) ou autre dispositif vasculaire (DV) (http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-01/11_01_check-list-cvc-dv.pdf).

- O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. *Am J Infect Control* 2011;39:Suppl 1:S1-34.
- O'Leary R, Ahmed SM, McLure H, et al. Ultrasound-guided infraclavicular axillary vein cannulation: a useful alternative to the internal jugular vein. *Br J Anaesth* 2012;109:762-8.
- Fragou M, Gravvanis A, Dimitriou V, et al. Real-time ultrasound-guided subclavian vein cannulation versus the landmark method in critical care patients: a prospective randomized study. *Crit Care Med* 2011;39:1607-12.

DOI: 10.1056/NEJMc1600131

TO THE EDITOR: Parienti et al. report catheter-related infectious and thrombotic complications of central venous catheterization according to insertion site. They chose compression ultrasonography as the diagnostic standard for deep-vein thrombosis (DVT). Although compression ultrasonography alone has efficacy that is similar to that of combined-method ultrasonography (color Doppler ultrasonography combined with compression ultrasonography) in diagnosing DVT in the legs,¹ this might not be the case for DVT in the arms. The vascular insertion site of subclavian-vein catheterization is usually located beneath the clavicle, which makes it difficult for the site to be visualized or compressed with compression ultrasonography. Color Doppler ultrasonography has been shown to be more sensitive and accurate than compression ultrasonography in diagnosing DVT in the arms.² The American College of Chest Physicians guidelines also suggest initial evaluation with combined-method ultrasonography over other initial tests in patients with suspected DVT in the arms.³ Using compression ultrasonography alone to diagnose subclavian-vein thrombosis might lead to underestimation of the event rate.

Li-Ta Keng, M.D.

National Taiwan University Hospital Hsin-Chu Branch
Hsin-Chu, Taiwan
ltkeng@gmail.com

No potential conflict of interest relevant to this letter was reported.

- Poppiti R, Papanicolaou G, Perese S, Weaver FA. Limited B-mode venous imaging versus complete color-flow duplex venous scanning for detection of proximal deep venous thrombosis. *J Vasc Surg* 1995;22:553-7.
- Prandoni P, Polistena P, Bernardi E, et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. *Arch Intern Med* 1997;157:57-62.
- Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2012;141:2 Suppl:e351S-418S.

DOI: 10.1056/NEJMc1600131

TO THE EDITOR: Parienti et al. report that use of the subclavian site for catheter insertion was associated with lower risks of infection and thrombosis but a higher risk of pneumothorax than use of the jugular or femoral sites. Although these results may be explained by the choice of anatomical site alone, there are other factors of equal or greater importance. Rates of ultrasonographic guidance for catheter insertion were low, which could explain the reported rates of insertion failure, hematoma, and pneumothorax. Systematic reviews show that the use of ultrasonographic guidance for central venous cannulation is associated with fewer complications than without such guidance.^{1,2} Chlorhexidine skin preparation was used less than 50% of the time, and chlorhexidine-impregnated dressings were not used.³ Less than 60% of the catheters were removed when no longer required. Appropriate indications for central-venous-catheter placement, the use of insertion bundles, proper catheter care (including the use of chlorhexidine-impregnated dressings),⁴ daily needs assessment, and prompt removal of catheters when no longer needed may be more important than the insertion site.

Philippe R. Bauer, M.D., Ph.D.

Craig E. Daniels, M.D.

Priya Sampathkumar, M.D.

Mayo Clinic
Rochester, MN
bauer.philippe@mayo.edu

No potential conflict of interest relevant to this letter was reported.

- Brass P, Hellmich M, Kolodziej L, Schick G, Smith AF. Ultrasound guidance versus anatomical landmarks for internal jugular vein catheterization. *Cochrane Database Syst Rev* 2015;1: CD006962.
- Brass P, Hellmich M, Kolodziej L, Schick G, Smith AF. Ultrasound guidance versus anatomical landmarks for subclavian or femoral vein catheterization. *Cochrane Database Syst Rev* 2015;1: CD011447.
- Mimoz O, Lucet JC, Kerforne T, et al. Skin antisepsis with chlorhexidine-alcohol versus povidone iodine-alcohol, with and without skin scrubbing, for prevention of intravascular-catheter-related infection (CLEAN): an open-label, multicentre, randomised, controlled, two-by-two factorial trial. *Lancet* 2015;386:2069-77.
- Safdar N, O'Horo JC, Ghufuran A, et al. Chlorhexidine-impregnated dressing for prevention of catheter-related bloodstream infection: a meta-analysis. *Crit Care Med* 2014;42:1703-13.

DOI: 10.1056/NEJMc1600131

THE AUTHORS REPLY: Vinson et al. raise the issue of ventilation status. The majority of catheterizations were performed with positive-pressure ventilation (2859 of 3471 [82.4%]) and positive end-expiratory pressure (PEEP) ventilation (2676 of 3471 [77.1%]). The higher risk of pneumothorax

associated with the use of PEEP than with non-use is difficult to assess, because the PEEP was turned off at the inserter's discretion during catheterization.

In response to Urbancic et al.: we used a rigorous definition of catheter-related bloodstream infection,¹ not the less accurate surveillance definition of central-catheter-associated bloodstream infection to which they refer. The former definition requires specific laboratory testing in order to unambiguously identify the catheter as the source of the bloodstream infection, whereas the latter definition indicates a bloodstream infection that occurred in the presence of a central catheter or within 48 hours after its removal, without any obvious other cause except the catheter. The low incidence of central-catheter-associated bloodstream infection that they report may relate to a different case mix or the use of chlorhexidine-coated catheters, which were not used in our trial. Given their low rate of pneumothorax, they could decrease further their incidence of central-catheter-associated bloodstream infection by adding the CDC and Australian and New Zealand Intensive Care Society guidelines recommendation "prefer the subclavian site" to their local protocol.

The risk of subclavian-vein stenosis² described by Corbett and Ashby has been associated with dialysis catheters. We excluded these devices.

Maizel and Slama may have misinterpreted the guidelines for catheterization³ in the subclavian vein, which state, "We suggest that ultrasound dynamic guidance is of limited value for most operators to guide subclavian-vein catheterization in adult patients (and that landmark technique is used instead)." Our multicenter trial reflects current real-world practice in France, with ultrasonography used at the discretion of the operator.

Keng informs us about the sensitivity of compression ultrasonography to diagnose subclavian DVT. The rate of Doppler-defined subclavian DVT ranged from 2 cases per 107 catheters (1.9%) to 8 cases per 123 catheters (6.5%) in previous trials,⁴ and we found a rate of 21 cases per 401 catheters (5.2%).

We agree with Bauer and colleagues that factors other than the insertion site can influence the risk of intravascular complications, but the site access was randomized. The CDC guidelines available when our trial was initiated¹ stated, "No comparison has been made between using chlorhexidine preparations with alcohol and povidone-iodine in alcohol to prepare clean skin. Unsolved issue." The results of the CLEAN trial⁵ were not available when we initiated or conducted our trial. Nevertheless, the incidence of catheter-related bloodstream infections in that trial was similar with chlorhexidine preparations and povidone-iodine preparations ($P=0.51$) for central venous catheters.

Jean-Jacques Parienti, M.D., Ph.D.

Normandie Université
Caen, France
parienti-jj@chu-caen.fr

Damien du Cheyron, M.D., Ph.D.

Centre Hospitalier Universitaire de Caen
Caen, France

Leonard A. Mermel, D.O.

Warren Alpert Medical School of Brown University
Providence, RI

for the 3SITES Study Group

Since publication of their article, the authors report no further potential conflict of interest.

1. O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. *Am J Infect Control* 2011;39:Suppl 1:S1-34.
2. Parienti JJ, Thirion M, Mégarbane B, et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. *JAMA* 2008;299:2413-22.
3. Frankel HL, Kirkpatrick AW, Elbarbary M, et al. Guidelines for the appropriate use of bedside general and cardiac ultrasonography in the evaluation of critically ill patients — part I: general ultrasonography. *Crit Care Med* 2015;43:2479-502.
4. Ge X, Cavallazzi R, Li C, Pan SM, Wang YW, Wang FL. Central venous access sites for the prevention of venous thrombosis, stenosis and infection. *Cochrane Database Syst Rev* 2012;3:CD004084.
5. Mimos O, Lucet JC, Kerforne T, et al. Skin antisepsis with chlorhexidine-alcohol versus povidone iodine-alcohol, with and without skin scrubbing, for prevention of intravascular-catheter-related infection (CLEAN): an open-label, multicentre, randomised, controlled, two-by-two factorial trial. *Lancet* 2015;386:2069-77.

DOI: 10.1056/NEJMc1600131

Pregnancy, Primary Aldosteronism, and Somatic *CTNNB1* Mutations

TO THE EDITOR: Teo et al. (Oct. 8 issue)¹ describe three women with aldosterone-producing adenomas. Each adenoma had a somatic mutation in

CTNNB1, the gene encoding β -catenin in the Wnt cell-differentiation pathway. The authors suggest that there is an association among a somat-